The Q2 2021 IngenioRx Drug and Biologic Pipeline Update highlights several emerging therapies in the pharmaceutical pipeline and provides an overview of significant Food and Drug Administration approvals to expect in 2021. We offer a recap on approvals from 2020 and predict how 2021 may compare. In addition, we examine the potential expansion of use for diabetes medications to other cardiovascular indications. We analyze the multiple sclerosis treatment and pipeline landscapes, as well as the opioid epidemic’s impact on the pipeline. Finally, we check on the status of interchangeable Humira biosimilars.
We continue to closely monitor the drug and biologic pipeline and provide this publication as part of our goals to improve health, reduce waste, lower total cost of care, and estimate future cost impact.